Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 11/20 | 0.54 |
| ▸ | PLAT | P00750 | 3/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | PLG | P00747 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14917060 | 1.00 | PLAU (0.54) | PLAUPLATCYP2C9CYP2D6ALDH1A1 | |
| SCHEMBL14917059 | 1.00 | PLAU (0.54) | PLAUPLATCYP2C9CYP2D6ALDH1A1 | |
| SCHEMBL14119962 | 0.80 | PLAU (0.39) | PLAUPLATCYP2C9CYP2D6ALDH1A1 | |
| SCHEMBL14119902 | 0.80 | CYP2C9 (0.33) | PLAUCYP2C9CYP2D6CYP1A2CYP19A1 | |
| SCHEMBL14119964 | 0.80 | PLAU (0.39) | PLAUPLATCYP2C9CYP2D6ALDH1A1 | |
| SCHEMBL14232278 | 0.80 | CYP2C9 (0.33) | PLAUCYP2C9CYP2D6CYP1A2CYP19A1 | |
| SCHEMBL14119899 | 0.80 | CYP2C9 (0.33) | PLAUCYP2C9CYP2D6CYP1A2CYP19A1 | |
| SCHEMBL24387226 | 0.77 | PLAU (0.54) | PLAUCYP2C9CYP2D6ALDH1A1MAPK1 | |
| SCHEMBL29749760 | 0.77 | PLAU (0.54) | PLAUCYP2C9CYP2D6ALDH1A1MAPK1 | |
| SCHEMBL28852779 | 0.75 | CYP2C9 (0.35) | PLAUCYP2C9CYP2D6CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2773640-B1 | BICYCLIC PIPERAZINE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2015-08-19 | — | — | EP | disclosed |
| US-8722676-B2 | Bicyclic piperazine compounds | GENENTECH, INC. (US) | 2014-05-13 | — | — | US | disclosed |
| US-20130116262-A1 | BICYCLIC PIPERAZINE COMPOUNDS | GENENTECH, INC. (US) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116262-A1 | BICYCLIC PIPERAZINE COMPOUNDS | BTK, LCK, SYK | PLAU 3841/4885PLAT 3334/4885CYP2C9 4268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.